ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.04−0.10 (-9.13%)
Close on Nov 13, 2026Market cap $315.93MP/E –Yield –
ProKidney r&d expenses
Research and development expenses are spending on new products and technology.
ProKidney's R&D Expenses for the twelve months ending Sep 30, 2026 was $144.94M, up 21.0% year over year. For fiscal 2025 it was $114.12M, down 10.6% from the year before. The highest annual figure on record is $127.67M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.12M | -10.6% |
| FY2024 | Dec 31, 2024 | $127.67M | +19.6% |
| FY2023 | Dec 31, 2023 | $106.71M | +30.0% |
| FY2022 | Dec 31, 2022 | $82.07M | +77.4% |
| FY2021 | Dec 31, 2021 | $46.26M | +119.8% |
| FY2020 | Dec 31, 2020 | $21.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $40.85M | +52.3% |
| Q2 FY2026 | Jun 30, 2026 | $36.10M | +39.5% |
| Q1 FY2026 | Mar 31, 2026 | $33.84M | +24.1% |
| Q4 FY2025 | Dec 31, 2025 | $34.16M | -14.1% |
| Q3 FY2025 | Sep 30, 2025 | $26.82M | -14.2% |
| Q2 FY2025 | Jun 30, 2025 | $25.88M | -12.0% |
| Q1 FY2025 | Mar 31, 2025 | $27.26M | +0.1% |
| Q4 FY2024 | Dec 31, 2024 | $39.78M | +76.6% |
| Q3 FY2024 | Sep 30, 2024 | $31.25M | -2.9% |
| Q2 FY2024 | Jun 30, 2024 | $29.40M | +11.5% |
| Q1 FY2024 | Mar 31, 2024 | $27.23M | +6.3% |
| Q4 FY2023 | Dec 31, 2023 | $22.53M | +7.8% |
| Q3 FY2023 | Sep 30, 2023 | $32.20M | +52.4% |
| Q2 FY2023 | Jun 30, 2023 | $26.36M | +128.1% |
| Q1 FY2023 | Mar 31, 2023 | $25.62M | -10.1% |
| Q4 FY2022 | Dec 31, 2022 | $20.89M | +95.5% |
| Q3 FY2022 | Sep 30, 2022 | $21.13M | +43.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.56M | – |
| Q1 FY2022 | Mar 31, 2022 | $28.49M | – |
| Q4 FY2021 | Dec 31, 2021 | $10.69M | – |
| Q3 FY2021 | Sep 30, 2021 | $14.74M | – |
See a number that looks wrong?